FRAX assessment. The patient. The patient. Which drug? UK NOGG Guidance 3/22/17. Safety issues with osteoporosis treatments
|
|
- Byron Hart
- 5 years ago
- Views:
Transcription
1 The patient Safety issues with osteoporosis treatments 78 year-old lady, retired dentist, active. Family history of osteoporosis (mother, younger sister). Humerus fracture 3 months ago. Type 2 diabetes since 1990, good glycaemic control, microalbuminuria. Creatinine clearance 40 ml/min by C-G formula. Bo Abrahamsen The patient FRAX assessment 78 year-old lady, retired dentist, active. Family history of osteoporosis (mother, younger sister). Humerus fracture 3 months ago (fall). Type 2 diabetes since 1990, good glycaemic control, microalbuminuria. Creatinine clearance 40 ml/min by C-G formula. Other biochemistry unremarkable. 25OHD 80 nmol/l. T-score -3.0 at L2-L4 spine (osteoporosis) -2.8 at femoral neck (osteoporosis) Meds Metformin, losartan, calcium + vitd 20 cigarettes daily, no alcohol UK NOGG Guidance Which drug? First choice: Weekly oral bisphosphonate (PROS: cheap, good efficacy, guidelines in favour, can be taken at home. CONS: adherence can be poor, GI tolerance issues) Fortunately I think you should be able to manage this on a tablet once a week. These drugs have been available for a long time so we have a lot of experience with them and the price is really low. 1
2 Patient concerns I don t want osteonecrosis of the jaw, I ve seen pictures and it is a condition that is far worse than a bone fracture. This drug has also been linked to cancer of the oesophagus. This is usually incurable. ONJ fact sheet Clinical diagnosis based on exposed visible bone in oral cavity seen by health professional, present > 8 wks. More than 95% of cases in the literature have occurred in patients with metastatic bone disease receiving long-term, high-dose, i.v. BP, in whom the estimated incidence is 1 to 12% at 36 months of exposure (annual cumulative oncology dose is about 10x the dose used for osteoporosis). Risk factors: invasive dental procedures, dental disease, poorly fitting dental appliances, tobacco/alcohol and corticosteroids or chemotherapeutic drugs. Prevalence rates in osteoporosis patients generally around 0.02% though one study reported prevalence up to 4.3%. No association with duration of use shown. Not necessary for patients (except oncology) to undergo dental evaluation or complete dental treatments prior to initiation of BP. See a dentist on a regular basis, maintain good oral hygiene. Should the need to perform an invasive dental procedure arise after therapy is initiated, there is no evidence that discontinuation of BP will improve dental outcome. Bone turnover markers non-informative. Suresh, Pazianas, Abrahamsen: Rheumatology (Oxford) (1):19-31 Oesophageal cancer fact sheet Upper GI issues with oral BPs in general Rare disease. Associated with smoking and alcohol use which are also risk factors for osteoporosis. Men > Women. Oral BPs: Meta-analysis of seven epidemiological studies (Sun, Osteoporosis Int 2013;24:27986) Pooled RR of 1.23 (95% CI 0.79, 1.92 ns) for cohort studies Pooled RR of 1.24 (95% CI 0.98, 1.57 ns) for case control studies Oesophageal cancer has very poor survival yet no excess oesophageal cancer deaths in alendronate users (Abrahamsen, JBMR 2012): 12,000 alendronate users followed for 6 years: 0.11% died of oesophageal cancer. All cause mortality 32.1%. 48,000 control subjects followed for 6 years: 0.15% died of oesophageal cancer. All cause mortality 34%. (study also found alendronate users had half the risk of gastric cancer and gastric cancer mortality compared with background). Upper GI irritation heartburn - is the most common side effect with oral BPs and reason most commonly given by patients for stopping treatment. Although not demonstrated in clinical trials, fewer GI side effects have been noted w/ weekly or monthly BP, compared with daily BP, in post-marketing reports. Note that some patients may (inappropriately) take the drug with a small amount of yoghurt or milk to alleviate this. Not the way forward obviously. I never prescribe PPIs to help patients tolerate oral BPs; change to other drug (often zol or dmab). Suresh, Pazianas, Abrahamsen: Rheumatology (Oxford) (1):19-31 Important safety considerations when discussing best medication for the patient Renal function Upper GI problems Dental status and planned procedures Important safety considerations when discussing best medication for the patient Renal function Upper GI problems Dental status and planned procedures 2
3 The patient 78 year-old lady, retired dentist, active. Family history of osteoporosis (mother, younger sister). Humerus fracture 3 months ago (fall). Type 2 diabetes since 1990, good glycaemic control, microalbuminuria. Creatinine clearance 40 ml/min by C-G formula. Other biochemistry unremarkable. 25OHD 80 nmol/l. T-score -3.0 at L2-L4 spine (osteoporosis) -2.8 at femoral neck (osteoporosis) Meds Metformin, losartan, calcium + vitd 20 cigarettes daily, no alcohol Patient agrees to start alendronate 70 mg once weekly 3 months consult with nurse, no tolerability issues Safety concerns with bisphosphonates Irrespective of duration Reflux / dyspepsia (oral) Renal toxicity (iv>oral) Hypocalcaemia (iv) Uveitis ONJ Acute phase reaction Musculoskeletal pain Atrial fibrillation (?) Liver toxicity (extremely rare) Probably unsafe in pregnancy/lactation (so absolutely avoid!) Long term use only Atypical femur fracture Reyes, J Cell Biochem Jan;117(1):20-8 ONJ AF AFF ASBMR 2014 definition of AFF BBC 1 st of March 2017 Kim, JBMR 2016 A femur fracture located along the diaphysis from just distal to the lesser trochanter to just proximal to the supracondylar flare. With at least four of these five major criteria met: Minimal or no trauma, as in a fall from a standing height or less Fracture line originates at the lateral cortex and is substantially transverse in its orientation, although it may become oblique as it progresses medially across the femur. Complete fractures extend through both cortices and may be associated with a medial spike; incomplete fractures involve only the lateral cortex The fracture is non-comminuted or minimally comminuted Localized periosteal or endosteal thickening of the lateral cortex is present at the fracture site ( beaking or flaring ) Minor or inconstant features: Generalized increase in cortical thickness of the femoral diaphyses Prodromal symptoms such as dull or aching pain in the groin or thigh Bilaterality Delayed fracture healing Shane E, JBMR 2014 Atypical femur fracture what should I do? Diagnosis is usually by conventional X-ray though CT or bone isotope scan often helpful. A DXA scan application has been developed (15-sec SE Femur Exam with high resolution image of the entire femur with low effective radiation dose performed at the time of a hip BMD scan). Always check opposite femur for similar lesion. Treatment surgery for all complete and most incomplete fractures (often persisting pain, delayed healing or progress to complete fractures). Teriparatide to stimulate healing? Prudent to stop antiresorptives if AFF develops. AFF, Hip Fractures and Deaths Number of fractures in One year Deaths first Excess deaths SMR Sweden mortality year first year Sutroch/shaft 5,342 fractures Excluded 4,218 AFF 172 0% 0.92 None None non-aff % Hip fractures 42,993 22% 3.4 9,458 7,309 Kharazmi JBMR 2016, Abrahamsen & Prieto-Alhambra JBMR
4 Age adjusted rate per 100, Fracture rate by adherence and year 522,287 female new BP users US Medicare Hip fractures (FN and IT) Harm Benefit MPR<1/3 MPR 1/3-2/3 MPR>2/3 400 Subtrochanteric and femoral shaft fractures MPR>2/3 200 MPR 1/3-2/3 MPR<1/ Year of treatment Risk of ST/FS and hip fractures OR and 95%CI for OR and 95% CI for ST/FS FRACTURE HIP FRACTURE Alendronate User status a Past user ( 1 year before) Reference Reference Recent user (<1y before) 1.00(0.82 to 1.25) p= (0.74 to 0.86) p<0.001 Current user 0.92(0.79 to 1.07) p= (0.65 to 0.77) p<0.001 MPR b <50% Reference Reference 50-80% 1.04(0.84 to 1.27) p= (0.89 to 1.08) p=0.65 >80% 0.90(0.78 to 1.03) p= (0.69 to 0.79) p<0.001 Dose years c <5 Reference Reference (0.87 to 1.28) p= (0.67 to 0.83) p< (0.45 to 1.14) p= (0.55 to 0.97) p=0.027 Two (ST/FS and hip, respectively) nested case-control analyses in Danish alendronate user-only cohort, treatment start (N=63,774) followed to end of Logistic regression adjusted for comorbid condition, prior fractures and comedications. Data from table 2, Wang et al, Ost Int Abrahamsen, BMJ 2016 The patient after 2 years on aln 80 year-old lady, retired dentist, active. Family history of osteoporosis (mother, younger sister). Type 2 diabetes since 1990, good glycaemic control, microalbuminuria. Creatinine clearance now 30 ml/min by C-G formula. Other biochemistry unremarkable. 25-OHD 96 nmol/l. T-score -2.9 at L2-L4 spine (osteoporosis) no sig change -2.7 at femoral neck (osteoporosis) no sig change Meds Metformin, losartan, alendronate, calcium + vitd No side effects, no new complaints, no falls or fractures No longer smokes, no alcohol Options Raloxifene (no) Zoledronic acid (no) Strontium ranelate (no) Risedronate?? Denosumab Safety concerns with denosumab Denosumab post marketing safety Irrespective of duration Infections Hypocalcaemia Cataracts? (men) ONJ Pain Flatulence Probably unsafe in pregnancy/lactation (so avoid) Long term use only Atypical femur fracture Post-marketing safety surveillance data for ProliaÒ had recorded four cases of atypical femur fracture meeting the ASBMR case definition. All patients had previously been bisphosponate users. There were also 32 reports of ONJ and eight cases of severe symptomatic hypocalcaemia; seven of the latter cases were in patients with CKD. Five cases of anaphylaxis were recorded, generally on the day of injection. There were no fatal cases of anaphylaxis. Estimated exposure with Prolia Ò was 1.2 million patient years. Suresh, Cleveland Clin J Med Feb;82(2): Geller, abstract ECCEO
5 Safety concerns with forteo/tpd Irrespective of duration Fatigue Headache Bone pain Hypercalcaemia Probably unsafe in pregnancy/lactation Long term use only Osteosarcoma?? (young rat model) Activation of dormant bone metastases?? Albumin adjusted calcium level of 1.32 mmol/l ( mmol/l) Phosphate 0.66 mmol/l ( ) Parathyroid hormone 28.0 pmol/l ( pmol/l) Communicating risk in osteoporosis The challenge of selecting an appropriate scale Brown, Can Fam Physician 2014;60: Red flags in the bone clinic Red flags in the bone clinic Renal function Renal function Pregnancy Osteomalacia Osteomalacia Hypoparathyroidism 5
6 Key points Important to consider renal function when prescribing. Particularly critical with zoledronic acid but true for all osteoporosis drugs (all are nominally contraindicated at crea/clearance < 30 ml, alendronate and zol at <35 ml. Be mindful of a history of upper GI complaints and chronic PPI use if prescribing oral bisphosphonates. Vitamin D status, renal function and intact PTH axis important when prescribing potent parenteral antiresorptives (dmab and zol) otherwise risk of life threatening hypocalcaemia. Key points Cardiovascular concerns (stroke, deep vein thrombosis) with raloxifene and strontium ranelate make these drugs less useful in the older patient. Atypical femur fractures are very rare and survival seems to be much better than after a hip fracture. Treatment is surgery. Easy to miss incomplete fracture as thigh or hip pain may have a multitude of causes (so be vigilant). ONJ is extraordinarily rare in osteoporosis patients but if possible then wait till elective dental work including implants has been completed if already planned. Good dental hygiene recommended. Inform patients despite rarity of this AE. 6
TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Honoraria: Amgen, Merck, Shire Consulting : AbbVie, Amgen, Merck,
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.
4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationOsteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017
Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Introduction A fracture due to OP occurs every 3 seconds around the world. 1
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationBalancing the Risks and Benefits of Osteoporosis Treatment: part I: 3 to 5 years treatment
Balancing the Risks and Benefits of Osteoporosis Treatment: part I: 3 to 5 years treatment Dennis M. Black, PhD Department of Epidemiology and Biostatistics, UCSF Financial Disclosures (past 3 years) -Consulting
More informationDisclosures D. Black. Bisphosphonates: Background, Efficacy and Recent Controversies. Page 1. Research Funding: Novartis, Merck
Bisphosphonates: Background, Efficacy and Recent Controversies Disclosures D. Black Research Funding: Novartis, Merck Dennis M. Black, PhD Consulting: Amgen, Lilly, Zosano, Nycomed Dept. of Epidemiology
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationPHYSICIAN OFFICE BILLING INFORMATION SHEET FOR XGEVA. Notes
For prevention of skeletal-related events XGEVA is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors. XGEVA is not indicated for the prevention
More informationS H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204
More informationFracture=Bone Attack:
Fracture=Bone Attack: Linking Hip Fractures to Osteoporosis Care Angela M. Cheung, MD, PhD, FRCPC Professor of Medicine, University of Toronto Potential Conflicts of Interests Industry Grants (to UHN)
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationHow to treat osteoporosis With what and for how long?
How to treat osteoporosis With what and for how long? Professor Neil Gittoes Consultant Endocrinologist & Honorary Professor Where will we be going? Drug therapies Current Indications Contraindications/unmet
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationAtypical Femoral Fractures Insights and Enigmas
Atypical Femoral Fractures Insights and Enigmas Madhu Mehta, M.D. Clinical Asst. Prof. of Medicine Department of Immunology/Rheumatology The Ohio State University Abreviations used TFF- Typical femoral
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationUsing GE Lunar DXA to Quantify, Visualize, and Trend Incipient Atypical Femoral Fractures
Using GE Lunar DXA to Quantify, Visualize, and Trend Incipient Atypical Femoral Fractures The management of osteoporosis underwent a paradigm shift in 1995 with the approval of the first bisphosphonate,
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationClodronate BE/H/PSUR/001/001 October 2011 Agreed CSP
Clodronate BE/H/PSUR/001/001 October 2011 Agreed CSP 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Intravenous use Treatment of hypercalcemia due to malignancy. Oral use Treatment of hypercalcemia
More informationAtypical Femoral Fractures With Long Term Bisphosphonates Use
Atypical Femoral Fractures With Long Term Bisphosphonates Use There has been an increase in the number of atypical femoral fractures in pa4ents on long term bisphosphonate therapy (e.g Fosamax) Accordingly
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationAdministration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures
Administration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures 2017 18 1. Purpose of Agreement This agreement outlines the expectations
More informationSummary of the risk management plan by product
Summary of the risk management plan by product 1 Elements for summary tables in the EPAR 1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Important potential risks
More informationBisphosphonates Length of treatment in osteoporosis in primary care- Treatment holiday
Bisphosphonates Length of treatment in osteoporosis in primary care- Treatment holiday This guidance incorporate National Osteoporosis Guideline Group (NOGG) guidance March 2017 Clinical guideline for
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationFOSAMAX (Alendronic acid as alendronate sodium trihydrate)
CSP - UK/H/PSUR/0070 - March 2012 EUROPEAN UNION CORE SAFETY PROFILE FOSAMAX (Alendronic acid as alendronate sodium trihydrate) 4.2 Posology and method of administration The recommended dosage is one 70
More informationAtypical Femoral Fracture: 2015 Position Statement of the Korean Society for Bone and Mineral Research
J Bone Metab 2015;22:87-91 http://dx.doi.org/10.11005/jbm.2015.22.3.87 pissn 2287-6375 eissn 2287-7029 Review Article Atypical Femoral Fracture: 2015 Position Statement of the Korean Society for Bone and
More informationATYPICAL FEMORAL FRACTURES AFTER LONG-TERM BISPHOS- PHONATES THERAPY: CASE REPORT
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2016 vol. 120, no. 1 INTERNAL MEDICINE - PEDIATRICS CASE REPORTS ATYPICAL FEMORAL FRACTURES AFTER LONG-TERM BISPHOS- PHONATES THERAPY: CASE REPORT Corina Găleşanu 1,3*,
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationOsteoporosis in practice. Katie Moss Rheumatology Consultant St George s Hospital London
Osteoporosis in practice Katie Moss Rheumatology Consultant St George s Hospital London Disclosures Lilly Educational grant and advisory board Prostrakan Educational grant Osteoporosis Case history 66
More informationTherapeutic Updates in the Prevention and Treatment of Osteoporosis
Therapeutic Updates in the Prevention and Treatment of Osteoporosis 2013 Fall Managed Care Forum Las Vegas November 15, 2013 Steven T Harris MD FACP Clinical Professor of Medicine University of California,
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationScreening Guidelines: Women
The Situation 1 in 2 postmenopausal women and 1 in 5 older men will have an osteoporosis-related fracture in their lifetimes Osteoporosis Definition NIH Consensus Conference A skeletal disorder characterized
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More information9/9/2015 OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY DISCLOSURES
OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Stock options/holdings,
More informationRefracture Prevention The Role of Primary Care
MonashHealth Refracture Prevention The Role of Primary Care Professor Peter R Ebeling AO MBBS MD FRACP Head, Department of Medicine School for Clinical Sciences Monash Health Translation Precinct Monash
More informationAtypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
REVIEW JBMR Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research Elizabeth Shane,* David Burr,* Bo Abrahamsen,
More informationOsteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE This guideline incorporates some of the recommendations from SIGN, NICE, National Group (NOGG) and local expert opinion. It adopts
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationDenosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:
Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to
More informationACP Colorado-Evidence Based Management of Osteoporosis
ACP Colorado-Evidence Based Management of Osteoporosis Micol S. Rothman, MD Associate Professor of Medicine and Radiology Clinical Director Metabolic Bone Program University of Colorado School of Medicine
More informationHot Topics in Osteoporosis and Fracture Prevention
Hot Topics in Osteoporosis and Fracture Prevention Sid Feldman, MD CCFP (COE) FCFP Sandra Kim, MD, FRCPC November 15, 2018 Family Medicine Forum, Toronto Faculty/Presenter Disclosure Faculty: Sid Feldman
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 DIDRONEL 200 mg, tablets B/60 (CIP code: 345 098-5) DIDRONEL 400 mg, tablets B/14 (CIP code: 333
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationPage 1. Current and Emerging Strategies for Osteoporosis. Osteoporosis Warm-Up: Which of the Following is True?
Current and Emerging Strategies for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis Warm-Up:
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationClinical Specialist Statement Template
Clinical Specialist Statement Template Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Review of the dossier of the medicinal product included on the list of reimbursable medicines for a period
More informationCurrent and Emerging Approaches for Osteoporosis
Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis
More informationOsteoporosis Management in Older Adults
Osteoporosis Management in Older Adults Angela M Cheung, MD, PhD, FRCPC, CCD Professor of Medicine, University of Toronto Disclosures Relationship with Commercial Entities: Honoraria from: Amgen, Eli Lilly,
More informationMPharm Programme. Osteoporosis in Practice (L4) Louise Statham- Senior Lecturer in Clinical Pharmacy
MPharm Programme Osteoporosis in Practice (L4) Louise Statham- Senior Lecturer in Clinical Pharmacy Louise.statham@sunderland.ac.uk Slide 1 of 47 MPHM13 Module Introduction Aims This lecture will build
More informationRheumatology. keeping Joints in Motion. Treating and Preventing Fractures
Rheumatology keeping Joints in Motion Treating and Preventing Fractures Robin K. Dore, MD Clinical Professor of Medicine David Geffen School of Medicine at UCLA, Los Angeles CA Private practice, Tustin
More informationDumfries and Galloway. Treatment Protocol for Osteoporosis
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 REFERRAL CRITERIA FOR DEXA 3 TREATMENT 4 Non-Drug Therapy : for all 4 Non-Drug Therapy : in the
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationPatients should receive supplemental calcium and vitamin D, if dietary intake is inadequate (see PRECAUTIONS).
PRODUCT CIRCULAR Tablets Once Weekly 70 mg I. THERAPEUTIC CLASS Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone. is a bisphosphonate that acts as a
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationWho cares about fractures! is more important. October 3, 2014 CSIM Workshop Brian Wirzba, MD, FRCPC, FACP Clinical Professor Grey Nuns Hospital
Isn t Osteoporosis just a T Score less than 2.5?? Who cares about fractures! is more important. Why do I need to know this? October 3, 2014 CSIM Workshop Brian Wirzba, MD, FRCPC, FACP Clinical Professor
More informationElements for a Public Summary
Ibandronat Stada 50 mg film-coated tablets Ibandronat Stada 150 mg film-coated tablets 3.11.2014, Version V2.1 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary
More informationOutline. Switching treatment. Evidence from randomized trials. The effects of switching 7/8/2016. When and for whom? Steven Cummings, MD
Outline Switching treatment When and for whom? Steven Cummings, MD Focus on switching from alendronate or risedronate Evidence about the effects of switching on BMD Purposes of switching Symptoms Poor
More informationCase Report Combined Effect of a Locking Plate and Teriparatide for Incomplete Atypical Femoral Fracture: Two Case Reports of Curved Femurs
Case Reports in Orthopedics Volume 2015, Article ID 213614, 5 pages http://dx.doi.org/10.1155/2015/213614 Case Report Combined Effect of a Locking Plate and Teriparatide for Incomplete Atypical Femoral
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationDisclosure. Objectives. Osteoporosis. Major Public Health Concern Will I end up like my mother?
Everything a Pharmacist Needs to Know About Osteoporosis New Mexico Pharmacists Association Mid-Winter Meeting January 27-28, 2018 Albuquerque, NM Consulting Amgen, Radius Speaking Radius Disclosure E.
More informationDrugs Approved for Prevention and Treatment of Postmenopausal Osteoporosis
Other Treatments of Osteoporosis- Who Should Get Bisphosphonates David Slovik, M.D. Endocrine Unit Newton-Wellesley Hospital Massachusetts General Hospital Harvard Medical School Massachusetts Medical
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationOsteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital
Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More informationPathway from Fracture or Risk Factor to Treatment
Appendix 6A - Guidance on Diagnosis and Management of Osteoporosis Pathway from Fracture or Risk Factor to Treatment Fragility Fracture = fracture sustained from a low energy fall from standing height
More informationClinical Practice Guideline. Adult Osteoporosis. Version
Clinical Practice Guideline Adult Osteoporosis Version 1.1.2017 March, 2017 Table of Contents Introduction...5 Establishing the Diagnosis of Osteoporosis and Risk of Fracture(s)...5 Fracture Risk Assessment...
More informationManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment Report of a Task Force of the American Society for Bone and Mineral Research
Review Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment Report of a Task Force of the American Society for Bone and Mineral Research Robert A. Adler 1 *, Ghada El-Hajj Fuleihan 2
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationPage 1
Osteoporosis Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during
More informationOxford University Hospitals Guidelines for Adjuvant Bisphosphonate treatment for Post-Menopausal Women with Early Breast Cancer
Oxford University Hospitals Guidelines for Adjuvant Bisphosphonate treatment for Post-Menopausal Women with Early Breast Cancer Category: Summary: Guideline Adjuvant Bisphosphonate treatment for Post-Menopausal
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationBONIVA (ibandronate sodium)
BONIVA (ibandronate sodium) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationDENOSUMAB SHARED CARE GUIDLINES
DENOSUMAB LICENSING Denosumab (PROLIA ) is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and for bone loss associated with hormone ablation in men with
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationEach film-coated tablet contains 70 mg alendronic acid (as sodium trihydrate).
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Alendronat Sandoz Veckotablett 70 mg Film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 70
More informationA Review of Bone Health Issues in Oncology
A Review of Bone Health Issues in Oncology David L. Kendler MD FRCPC CCD Professor of Medicine (Endocrinology) University of British Columbia Vancouver Canada Disclosures David Kendler has received research
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More information